MiNK Therapeutics, Inc.
INKT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INKT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer, acute respiratory distress syndrome (ARDS), and graft-versus-host disease (GVHD), with a lead candidate AGENT-797 in Phase 2 trials.
Key risk: Limited cash runway
BioSniper Score
Based on 6 of 6 signals
Market Cap
$58.3M
Cash Runway
12.9 moLead Asset
agent-797 (Phase 1)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials · 1 catalyst for MiNK Therapeutics, Inc..
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer, acute respiratory distress syndrome (ARDS), and graft-versus-host disease (GVHD), with a lead candidate AGENT-797 in Phase 2 trials.
- Lead candidate AGENT-797 is being evaluated in a randomized Phase 2 clinical trial for ARDS and multidrug-resistant infections [sec · filed 2026-04-30].
- Cash and equivalents were $8.8 million as of 2026-06-30, with a net loss of $3.1 million for the same period [sec].
- Accumulated deficit reached $127.9 million as of a 2023 filing [sec · filed 2023-11-14].
- Pipeline includes preclinical CAR-iNKT programs targeting BCMA and tumor stroma, with IND filings expected in 2022 [sec · filed 2022-05-13].
What works
- AGENT-797 targets high-unmet-need indications (ARDS, GVHD, solid tumors) with no effective therapies currently available [sec · filed 2022-05-13].
- The company has initiated a randomized Phase 2 trial in ARDS, a potential pivotal study design [sec · filed 2026-04-30].
- Allogeneic iNKT platform offers off-the-shelf potential, reducing manufacturing complexity compared to autologous therapies [sec · filed 2022-05-13].
What to weigh
- Cash runway is limited: $8.8 million as of 2026-06-30 may not sustain operations beyond the near term without additional funding [sec].
- Accumulated deficit of $127.9 million (as of 2023) reflects a history of losses with no approved products or revenue [sec · filed 2023-11-14].
- Clinical development is lengthy and uncertain; the company cannot reliably estimate costs or timelines for regulatory approval [sec · filed 2023-11-14].
- Shareholders' equity is negative ($-14.2 million as of 2026-06-30), indicating a weak balance sheet [sec].
From the filings
Quoted directly from source documents.
AGENT-797 is in a randomized Phase 2 trial for ARDS.
“initiation of a randomized Phase 2 clinical trial in acute respiratory distress syndrome (ARDS) and multidrug-resistant infections”
SEC filings · April 30, 2026
Accumulated deficit was $127.9 million as of a 2023 filing.
“accumulated deficit of $127.9 million as of”
SEC filings · November 14, 2023
Preclinical CAR-iNKT programs target BCMA and tumor stroma.
“BCMA-CAR-iNKT, and (2) a tumor stromal targeting CAR-iNKT program”
SEC filings · May 13, 2022
Catalyst timeline
- 2026-12-31 · Phase2_Topline · agent-797 — Phase 2 Readout: agent-797 — Top-line data from the randomized Phase 2 trial of AGENT-797 in ARDS is expected, which could inform efficacy and future development.
Risks & what to watch (4)›
Key risks
- Limited cash runway — Only $8.8M cash as of 2026-06-30; may require near-term financing [sec].
- No approved products or revenue — History of losses since 2017; accumulated deficit $127.9M [sec · filed 2023-11-14].
- Clinical development uncertainty — Regulatory approval process is lengthy, expensive, and uncertain [sec · filed 2023-11-14].
- Negative shareholders' equity — Equity of -$14.2M as of 2026-06-30 indicates financial strain [sec].
What to watch
- Phase 2 top-line data for AGENT-797 in ARDS expected by 2026-12-31 [catalyst].
- Potential need for additional financing given $8.8M cash balance [sec].
- Progress of preclinical CAR-iNKT programs toward IND filings [sec · filed 2022-05-13].
- Any updates on partnership or out-licensing deals to extend runway [sec · filed 2022-08-15].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run MiNK Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MiNK Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
12.9 months
OCF -$2M · Net income -$3M
Lead: Phase 1
1 candidate
1 upcoming, next in ~123d
0 buys · 6 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$1.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 118,728 | $1.3M |
| geode capital management, llc | 17,345 | $183K |
| longbow finance sa | 16,667 | $176K |
| vanguard fiduciary trust co | 8,287 | $87K |
| blackrock, inc. | 6,203 | $65K |
| morgan stanley | 104 | $1K |
| citigroup inc | 91 | $958 |
| northwestern mutual wealth management co | 18 | $190 |
| bnp paribas financial markets | 16 | $168 |
| game plan financial advisors, llc | 16 | $168 |
Showing top 10 of 17 institutional holders of MiNK Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 4.0%
- Days to cover
- 1.7
- Shares short
- 97,106
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INKT short interestGovernance
Frequently asked questions
What is the AI investment thesis for MiNK Therapeutics, Inc.?
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer, acute respiratory distress syndrome (ARDS), and graft-versus-host disease (GVHD), with a lead candidate AGENT-797 in Phase 2 trials.
What is MiNK Therapeutics, Inc.'s lead drug candidate?
MiNK Therapeutics, Inc.'s most advanced tracked candidate is agent-797 (Phase 1) for Respiratory Distress Syndrome, Adult; Pneumonia.
What is MiNK Therapeutics, Inc.'s next catalyst?
MiNK Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: agent-797" — expected December 31, 2026.
Who is the CEO of MiNK Therapeutics, Inc.?
Dr. Jennifer S. Buell Ph.D. is the chief executive officer of MiNK Therapeutics, Inc. (INKT).
Where is MiNK Therapeutics, Inc. headquartered?
MiNK Therapeutics, Inc. (INKT) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.